finance.yahoo.com ·
alphatec q1 earnings call highlights 222314068
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAlphatec (medical device company focused on spine surgery) reported Q1 results with revenue below expectations due to weaker EOS performance, but surgical revenue and case volumes grew strongly. The company maintained full-year EBITDA and FCF targets, and secured a new credit facility to lower interest costs. The commercial mechanism is company-specific: revenue miss vs guidance, but margin improvement and cost savings from refinancing. No broad sector or supply chain impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $192M, +14% YoY, below internal expectations
- Surgical revenue +17% to $178M, cases +21%, surgeons +23%
- FY2026 revenue guidance ~$882M, adj. EBITDA ~$134M, FCF at least $20M
- Gross margin 71.6%, adj. EBITDA $21M (+97% YoY)
- Cash ~$140M, new credit facility to reduce interest expenses
Alphatec's maintained EBITDA and FCF guidance leads to flat impact for spine surgery implants in the mid-term; expected within 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.